仑伐替尼治疗放射性碘难治性甲状腺癌的真实世界实践
回顾性分析法国27个中心2015年7月至2016年6月连续接受仑伐替尼治疗的75例放射性碘难治性分化型甲状腺癌(rDTC)患者。中位无进展生存期为10个月,65例可评估患者中部分缓解23例(31%)、疾病稳定38例(51%)。不良反应频繁,44例(59%)减量、23例(31%)中断治疗。
要点
- 真实世界中rDTC患者可从仑伐替尼治疗中获益,中位无进展生存期10个月。
- 可评估的65例中部分缓解23例(31%)、疾病稳定38例(51%)。
- 不良反应频繁,44例(59%)减量和23例(31%)中断治疗,需密切监测。
核心结论
- 真实世界的rDTC患者可从仑伐替尼治疗中获益,但不良反应频繁,应密切监测。
研究设计与样本
- 回顾性分析法国27个中心2015年7月至2016年6月连续接受仑伐替尼治疗的88例患者病历,排除其他甲状腺癌类型11例和既往在试验中接受仑伐替尼2例后,75例rDTC患者纳入分析。
主要发现
- 75例rDTC患者中女性33例,中位年龄65岁(范围35-88岁),12例东部肿瘤协作组体能状态评分≥2,24例以仑伐替尼作为一线全身治疗,47例(63%)在治疗开始前有记录的疾病进展。
- 远处转移位于肺、骨和淋巴结的比例分别为89%、60%和69%。
- 初始治疗剂量为24 mg者54例,其余21例剂量更低;中位随访7个月,中位治疗持续时间6个月(范围0.3-15个月),中位无进展生存期10个月。
- 65例可评估肿瘤反应的患者中,最佳反应为部分缓解23例(31%)、疾病稳定38例(51%);11例(14.7%)因疾病进展停用仑伐替尼。
- 44例(59%)因不良事件减量、23例(31%)因不良事件中断治疗;最常见治疗相关不良事件为乏力、高血压、体重减轻、腹泻和厌食;研究期间死亡11例(其中1例被认为与药物相关);2例肺转移患者发生气胸。
临床怎么用
- 真实世界rDTC患者可从仑伐替尼治疗中获益,不良反应频繁,应密切监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: In the Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid (SELECT) phase 3 trial on advanced radioactive iodine-refractory differentiated thyroid cancer (rDTC), lenvatinib improved median progression-free survival over placebo by almost 15 months and induces an objective response rate of 64.8%, but adverse events occurred in almost all patients. The present study evaluates the efficacy and toxicity of lenvatinib treatment in real-life practice. Methods: Clinical charts of 88 consecutive patients treated with lenvatinib from July 2015 to June 2016 in 27 French centers were retrospectively reviewed. Patients treated for other thyroid cancer types (n = 11) or previously treated with lenvatinib within a trial (n = 2) were excluded and the remaining 75 rDTC patients formed the basis of this report. Results: 75 rDTC patients were analyzed (33 females, median age 65 years [range, 35-88 years]), 12 had an Eastern Cooperative Oncology Group performance status ≥2; 24 cases received lenvatinib as first line systemic treatment; 47 (63%) patients had documented progressive disease prior to treatment initiation. Distant metastases were located in lungs, bones, and lymph nodes (89%, 60%, and 69%, respectively). The initial treatment dose was 24 mg in 54 patients and was lower in the other 21 patients. The median follow-up was 7 months, with a median duration of treatment of 6 months [0.3-15]. Median progression-free survival was 10 months. Among the 65 patients with evaluation of tumor response during treatment, best tumor response was a partial response in 23 patients (31%) and stable disease in 38 (51%). Eleven patients (14.7%) discontinued lenvatinib because of disease progression. Forty-four (59%) and 23 (31%) patients had dose reductions or an interruption of lenvatinib for adverse events (AEs). The most frequent AEs related to treatment were fatigue, hypertension, weight loss, diarrhea, and anorexia. Eleven deaths occurred during the study (one considered to be drug related). Pneumothorax occurred in 2 patients with lung metastases. Conclusions: Real-life patients with rDTC can benefit from lenvatinib treatment. AEs are frequent and should be closely monitored.
引用
- Berdelou A, Borget I, Godbert Y, et al. Lenvatinib for the Treatment of Radioiodine-Refractory Thyroid Cancer in Real-Life Practice. Thyroid. 2017. PMID: 29048237. doi:10.1089/thy.2017.0205
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。